PCSK9 inhibitor therapy: delayed-onset cutaneous reactions

Authors

  • Shahid Bukhari Chelsea & Westminster Hospital
  • Aikaterini Theodoraki Chelsea & Westminster Hospital
  • Emily Ward Chelsea & Westminster Hospital
  • Edson Nogueira Chelsea & Westminster Hospita
  • Michael Feher Chelsea & Westminster Hospita

DOI:

https://doi.org/10.15277/bjd.2023.419

Keywords:

PCSK9-inhibitor, delayed cutaneous reaction

References

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardio- vascular outcomes after acute coronary syndrome. N Engl J Med 2018;379(22):2097-2107. https://doi.org/10.1056/NEJMoa1801174

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376(18):1713-22. https://doi.org/10.1056/NEJMoa1615664

Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther 2019;32(2):e12817. https://doi.org/10.1111/dth.12817

BJD December 2023 Cover

Downloads

Published

2023-12-18

Issue

Vol. 23 No. 2 (2023): December 2023

Section

Case Reports

License

Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.